Estimating the burden of type 2 diabetes in the UK prison environment for the next decade

Published:February 08, 2021DOI:https://doi.org/10.1016/j.pcd.2021.01.013

      Highlights

      • Health data was obtained through risk assessments undertaken in a prison setting.
      • Overall, 6.4 men per 100 in prison predicted to develop T2DM in next 10 years.
      • Predictions were highest in men aged 50 years and older (16.4 new cases per 100).

      Abstract

      Although limited, global evidence suggests that the cardiometabolic health of those in prison is poorer than their community peers. Type 2 diabetes (T2DM) is a public health challenge and community rates are continuing to rise. Given that cardiometabolic risk factors are prevalent amongst younger individuals within the prison population, it is reasonable to assume that the prison environment will also experience an increase in new cases of T2DM. Therefore, the aim of this study was, to predict in a current prison population, how many potential new cases of T2DM could develop in the next 10 years. This study used health data collected from a prison sample (n = 299) aged 25–84 years in HMP Parc, UK, and the Diabetes UK Risk Score was used to predict T2DM risk. In terms of projecting new cases, it was estimated that in the next decade 6.4 individuals per 100 would develop T2DM, and this value increased to 16.4 individuals per 100 in those aged 50 years and older. The development of new cases across all age groups is a concern, and it appears that the prison community are a ‘target population’ for prevention opportunities.

      Keywords

      To read this article in full you will need to make a payment
      Subscribe to Primary Care Diabetes
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Packham C.
        • Butcher E.
        • Williams M.
        • et al.
        Cardiovascular risk profiles and the uptake of the NHS Healthcheck programme in male prisoners in six UK prisons: an observational cross-sectional survey.
        BMJ Open. 2020; 10: 33498https://doi.org/10.1136/bmjopen-2019-033498
        • Wright N.M.J.
        • Hearty P.
        • Allgar V.
        Prison primary care and noncommunicable diseases: a data-linkage survey of prevalence and associated risk factors.
        BJGP Open. 2019; 3https://doi.org/10.3399/bjgpopen19X101643
        • Herbert K.
        • Plugge E.
        • Foster C.
        • et al.
        Prevalence of risk factors for non-communicable diseases in prison populations worldwide: a systematic review.
        Lancet (London, England). 2012; 379: 1975-1982https://doi.org/10.1016/S0140-6736(12)60319-5
        • Hannan-Jones M.
        • Capra S.
        Prevalence of diet-related risk factors for chronic disease in male prisoners in a high secure prison.
        Eur. J. Clin. Nutr. 2016; 70: 212-216https://doi.org/10.1038/ejcn.2015.100
        • D’Souza R.M.
        • Butler T.
        • Petrovsky N.
        Assessment of cardiovascular disease risk factors and diabetes mellitus in Australian prisons: is the prisoner population unhealthier than the rest of the Australian population.
        Aust. N. Z. J. Public Health. 2005; 29: 318-323https://doi.org/10.1111/j.1467-842X.2005.tb00200.x
        • Binswanger I.A.
        • Krueger P.M.
        • Steiner J.F.
        Prevalence of chronic medical conditions among jail and prison inmates in the USA compared with the general population.
        J. Epidemiol. Commun. Health. 2009; 63: 912-919https://doi.org/10.1136/jech.2009.090662
        • Munday D.
        • Leaman J.
        • O’Moore É
        • et al.
        The prevalence of non-communicable disease in older people in prison: a systematic review and meta-analysis.
        Age Ageing. 2019; 48: 204-212https://doi.org/10.1093/ageing/afy186
        • Saeedi P.
        • Petersohn I.
        • Salpea P.
        • et al.
        Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition.
        Diabetes Res. Clin. Pract. 2019; 157: 107843https://doi.org/10.1016/j.diabres.2019.107843
        • Gray B.J.
        • Craddock C.
        • Couzens Z.
        • et al.
        Abundance of undiagnosed cardiometabolic risk within the population of a long-stay prison in the UK.
        Eur. J. Public Health. 2020; (Published Online First)https://doi.org/10.1093/eurpub/ckaa187
      1. Diabetes UK. Know Your Risk of Type 2 diabetes. https://riskscore.diabetes.org.uk/start.

        • Ministry of Justice
        Offender management statistics quarterly: October to December 2019—GOV.UK.
        2020 (Accessed 25 January 2021)
        • National Institute for Health and Care Excellence
        Type 2 diabetes: prevention in people at high risk.
        2012: 1 (Accessed 10 February 2020)
        • Barron E.
        • Clark R.
        • Hewings R.
        • et al.
        Progress of the healthier you: NHS diabetes prevention programme: referrals, uptake and participant characteristics.
        Diabet. Med. 2018; 35: 513-518https://doi.org/10.1111/dme.13562
        • Charles A.
        • Draper H.
        ‘Equivalence of care’ in prison medicine: is equivalence of process the right measure of equity?.
        J. Med. Ethics. 2012; 38: 215-218https://doi.org/10.1136/medethics-2011-100083
        • Baxter M.
        • Hudson R.
        • Mahon J.
        • et al.
        Estimating the impact of better management of glycaemic control in adults with type 1 and type 2 diabetes on the number of clinical complications and the associated financial benefit.
        Diabet. Med. 2016; 33: 1575-1581https://doi.org/10.1111/dme.13062
        • World Health Organization Regional Office for Europe
        Prisons and Health.
        2014 (Accessed 24 January 2020)
        • Fine A.
        • Gallaway M.S.
        • Dukate A.
        Prevention in prison: the diabetes prevention program in a correctional setting.
        Diabetes Spectr. 2019; 32: 331-337https://doi.org/10.2337/ds18-0080
        • Tuomilehto J.
        • Lindström J.
        • Eriksson J.G.
        • et al.
        Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.
        N. Engl. J. Med. 2001; 344: 1343-1350https://doi.org/10.1056/NEJM200105033441801
        • Diabetes Prevention Program Research Group
        10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study.
        Lancet. 2009; 374: 1677-1686https://doi.org/10.1016/S0140-6736(09)61457-4